Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aclidinium bromide/formoterol - Covis Pharma

Drug Profile

Aclidinium bromide/formoterol - Covis Pharma

Alternative Names: Aclidinium bromide/formoterol - AstraZeneca; Aclidinium bromide/formoterol fumarate; BrimicaGenuair; Duaklir Pressair; Duaklir®; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Laboratorios Almirall
  • Developer Allergan; Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical; NIOX
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 25 Oct 2022 Positive topline efficacy and adverse event data from the phase III AVANT trial in Chronic obstructive pulmonary disease released by Covis Pharma
  • 14 Apr 2022 AstraZeneca in collaboration with Paraxel completes a phase III trials in Chronic obstructive pulmonary disease in Philippines, Vietnam, Taiwan, India and China (Inhalation) (NCT03022097)
  • 01 Nov 2021 Covis Pharma acquires aclidinium bromide/formoterol from AstraZeneca
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top